About Ceilidh Shea - Policy Advocate
Ceilidh has a strong interest in the intersection of public policy and health outcomes, particularly with respect to health equity and health justice. She is a graduate of Colorado College, where she majored in Political Science and minored in Global Health.
An exploration of policy solutions and consumer protections related to medical credit cards, the reporting of medical debt, hospital financial assistance programs and facility fees
A new report from the U.S. Department of Health and Human Services reveals just how impactful the prescription drug provisions of the Inflation Reduction Act (IRA) will be. The new data show the first 10 drugs subject to price negotiation under Medicare, starting in 2026, currently make up nearly 20 percent of the Medicare Part D benefit. In addition, Part B beneficiaries might see reduced coinsurances in 2024 because of the IRA’s inflation rebate provision.
It's worth it, therefore, to revisit this landmark legislation that puts affordability at the center of heath care policy objectives.
For many years, national polling has revealed that families in America struggle with the high cost of health care, and that health care costs impact decisions about insurance coverage and if and when to seek health care. In fact, health care costs rank as a top financial worry for people across the country.[1] Our survey results are consistent with nationwide trends; Maine families, like many families across the country, are struggling to afford and access the care and coverage they need.
